

REMARKS

In response to the restriction requirement which the Examiner imposed, Applicants elect, without traverse, to prosecute claims 19-21, *i.e.*, the Group II claims. Also provided is a new claim set, support for which is as follows:

<u>New Claim No.</u>	<u>Support (Original Claim No.)</u>
22	2
23	3
24	4
25	11
26	11
27	5
28	6
29	7
30	12
31	8
32	9
33	16
34	9

In addition, it is noted that only 10 sequences are allowed within any of the groups identified by the examiner. In this context, applicants wish to provide the following comments on the invention. The basis of the new (and original) claim set above is a composition comprising only one RT primer for several different MAGE gene transcripts. The client has ranked these primer sequences in claim 24 according to their priorities, primer MgRT3a being most preferred. In addition to such primer, the composition may comprise another type of primer (an RT primer for the calibrator mRNA). The client has ranked this additional type of

primer sequences in claim 29 according to their priorities, primer PBGD_RT15b being most preferred. Finally, claims 31 and 33 list primers for amplification of the reversely transcribed MAGE/calibrator RNAs. Thus, applicants understand the restriction requirement to require selection of 10 sequences of claim 24, but no such limitation would be required for claims 29, 31 and 33. Thus, applicants elect the sequence of subpart (A) of claim 24, and the first sequence of subpart (B).

The examiner is invited to contact the undersigned attorney at 512-536-3184 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3184

Date: March 23, 2007